Breaking News: Actuate Therapeutics (ACTU) Completes Enrollment in Phase 2 Pancreatic Cancer Trial

*Sponsored Market Crux Announces Actuate Therapeutics, Inc. (NASDAQ: ACTU) As Its Next Potential Breakout Idea… Here’s Why… Limited Share Availability: With a low float (<6M shares) and strong insider control (65%), this structure has the potential for volatility if demand begins to shift. Ongoing Clinical Trials: Actuate Therapeutics, Inc. (NASDAQ: ACTU) continues to evaluate elraglusib’s effectiveness in treating multiple cancer types. Key Event This Week: The B. Riley Oncology Conference on February 28th could bring important updates on Actuate Therapeutics, Inc. (NASDAQ: ACTU)’s clinical progress and research developments. Consider taking a look at (ACTU) before the bell rings… February 25, 2025 Dear Reader, We’ve got breaking news that just crossed the wire! Actuate Therapeutics, Inc. (NASDAQ: ACTU) has just announced the completion of patient enrollment in its Phase 2 trial evaluating elraglusib (9-ING-41) in combination with FOLFIRINOX and losartan for previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).  This milestone marks a significant step forward in the development of potentially more effective treatment options for one of the most challenging cancers. Key Highlights of the Announcement: ✔ Patient Enrollment Completed: 56 treatment-naïve mPDAC patients have been enrolled in this Phase 2 open-label, non-comparator study (NCT05077800). ✔ Early Clinical Activity Observed: Initial data presented at the AACR Special Conference on Advances in Pancreatic Cancer Research (Sept. 2024) revealed early evidence of enhanced clinical activity when elraglusib was combined with FOLFIRINOX and losartan in untreated mPDAC patients. ✔ Final Results Expected in 2026. ✔ Lead Investigator & Research Sites: The trial is led by Dr. Colin Weekes, MD, Ph.D. (Massachusetts General Hospital) with participation from University of Colorado (Dr. Cristopher Lieu, MD) and Fred Hutchinson Cancer Center (Dr. Andrew Coveler, MD). A Critical Step in Advancing Elraglusib Actuate Therapeutics, Inc. (NASDAQ: ACTU)’s President & CEO, Daniel Schmitt, emphasized the importance of this trial in establishing elraglusib as a promising new therapy for pancreatic cancer.  The company’s interim Phase 2 data from another study combining elraglusib with gemcitabine/nab-paclitaxel (GnP) has already demonstrated statistically significant improvements in 1-year and median overall survival in first-line mPDAC treatment. Dr. Weekes and his research team believe that the insights gained from this trial could contribute to the development of more effective treatments for metastatic pancreatic cancer. With pancreatic cancer being one of the most aggressive and deadly forms of cancer, this trial represents a meaningful step forward in research and treatment innovation. If you missed my earlier email on (ACTU), keep reading below to get caught up to speed before the bell rings. Today, the spotlight is on Actuate Therapeutics, Inc. (ACTU)—a clinical-stage biopharmaceutical company focused on developing breakthrough cancer treatments designed to address some of the toughest, most treatment-resistant cancers. Key Factors to Watch for (ACTU) Today With less than 6M shares in the float and over 65% insider ownership, (ACTU) has a tightly held structure that can lead to sharp movement if demand begins to shift.  A strong level of insider control suggests confidence in the company’s direction, while a low float can contribute to significant swings under certain conditions. Recent Market Recognition Actuate Therapeutics, Inc. (NASDAQ: ACTU) has seen strong market attention in recent weeks, posting a move of approximately 87% in about a month. December 23, 2024: (ACTU) was trending at at $6.27 January 23, 2025: (ACTU) reached $11.73 Now: (ACTU) is currently trending above its 5-day moving average of $7.67 after reaching $8.00 in pre-market trading today. This type of momentum suggests increased interest, particularly as the company moves forward with its clinical developments and upcoming events. Upcoming Event – February 28, 2025 Daniel Schmitt, President & CEO of Actuate Therapeutics, Inc. (NASDAQ: ACTU), will participate in the: B. Riley Precision Oncology & Radiopharma Conference Date: Friday, February 28, 2025 Location: New York, NY Format: Fireside chat + one-on-one meetings This event could bring key updates on clinical progress and provide further insights into Actuate’s work in developing novel therapies for treatment-resistant cancers. Advancing Cancer Research with a Unique Approach Actuate Therapeutics, Inc. (NASDAQ: ACTU) is working to develop treatments that go beyond conventional chemotherapy and radiation.  Its lead candidate, Elraglusib, is a GSK-3β inhibitor designed to disrupt cancer survival mechanisms and make tumors more responsive to treatment. How Elraglusib Targets Cancer Cells Many cancers become resistant to traditional treatments by activating DNA Damage Response (DDR) pathways, allowing tumors to repair themselves after chemotherapy or radiation.  Elraglusib blocks GSK-3β, an enzyme that supports these survival mechanisms. By interfering with this process, it may: ✅ Reduce cancer cell survival and proliferation ✅ Enhance the effectiveness of chemotherapy and radiation ✅ Limit the ability of tumors to recover from treatment A Dual Effect: Weakening Tumors & Engaging the Immune System Elraglusib is being studied not just for its direct impact on tumors but also for its role in supporting the body’s natural immune defense against cancer. Blocking NF-kB: Many aggressive cancers use NF-kB, a key protein complex, to suppress immune response and fuel tumor growth. Elraglusib works by inhibiting NF-kB, potentially restoring immune function and making tumors more vulnerable. Regulating Immune Checkpoints: Cancer cells often evade detection by manipulating immune checkpoints—molecular signals that tell the immune system to stand down. Elraglusib may help regulate these checkpoints, potentially enhancing the effectiveness of immune-based therapies. What’s Next for Actuate Therapeutics, Inc. (NASDAQ: ACTU)? With an innovative approach that combines direct tumor targeting with immune system support, Elraglusib represents a significant step forward in cancer research. Ongoing Clinical Trials: Actuate Therapeutics, Inc. (NASDAQ: ACTU) continues to evaluate elraglusib’s effectiveness in treating multiple cancer types. Limited Share Availability: With a low float (<6M shares) and strong insider control (65%), this structure has the potential for volatility if demand begins to shift. Key Event This Week: The B. Riley Oncology Conference on February 28th could bring important updates on Actuate Therapeutics, Inc. (NASDAQ: ACTU)’s clinical progress and research developments. With its focus on tackling treatment-resistant cancers and advancing new scientific approaches, Actuate Therapeutics, Inc. (NASDAQ: ACTU) is at the forefront of a rapidly evolving field.  Those following developments in medical research and breakthrough treatments will be watching closely. We have all eyes on Actuate Therapeutics, Inc. (NASDAQ: ACTU) right now. Consider taking a look at (ACTU) before the bell rings. Don’t miss the breaking news from (ACTU) that just crossed the wire. I’ll follow up with you shortly with an update—keep a lookout for it. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 02/25/2025 and ending on 02/25/2025 to publicly disseminate information about (ACTU:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their members own shares of (ACTU:US). Please see important disclosure information here: https://marketcrux.com/disclosure/actu/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice